Executive readout · one minute
What the filings say
- 8-K earnings release · filed Oct 27, 2026
- Beta Bionics reported third-quarter net sales of $35.5 million, up 30%, and a net loss of $24.4 million. Full-year 2026 revenue guidance increased to approximately $124 million to $126 million, while gross margin guidance remained 58.5% to 59.5%.
- 10-Q report · filed Oct 27, 2026
- Beta Bionics reported nine-month net sales of $95.1 million, up from $68.1 million, and a net loss of (69,651), compared with (59,734), in thousands.
The audio replay and transcript follow the call.